Northwest Biotherapeutics Inc
General ticker "NWBO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $347.3M
Northwest Biotherapeutics Inc does not follow the US Stock Market performance with the rate: -39.7%.
Estimated limits based on current volatility of 3.6%: low 0.25$, high 0.27$
Factors to consider:
- Current price 37.0% below estimated low
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.42$, 1.09$]
- 2024-12-30 to 2025-12-30 estimated range: [0.36$, 0.95$]
Financial Metrics affecting the NWBO estimates:
- Negative: Non-GAAP EPS, $ of -0.06 <= 0.10
- Negative: Operating profit margin, % of -96.64 <= 1.03
- Negative: Operating cash flow per share per price, % of -6.04 <= 2.35
- Negative: negative Net income
Short-term NWBO quotes
Long-term NWBO plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $1.00MM | $1.68MM | $1.93MM |
Operating Expenses | $53.71MM | $68.86MM | $57.44MM |
Operating Income | $-52.70MM | $-67.18MM | $-55.51MM |
Non-Operating Income | $231.83MM | $-37.85MM | $-7.09MM |
Interest Expense | $5.01MM | $6.07MM | $5.24MM |
R&D Expense | $20.31MM | $35.51MM | $27.73MM |
Income(Loss) | $179.13MM | $-105.03MM | $-62.60MM |
Taxes | $0.00MM | $31.82MM | $0.00MM |
Profit(Loss) | $179.13MM | $-136.85MM | $-62.60MM |
Stockholders Equity | $-123.99MM | $-128.10MM | $-65.77MM |
Assets | $40.16MM | $31.32MM | $27.86MM |
Operating Cash Flow | $-38.30MM | $-52.77MM | $-53.64MM |
Capital expenditure | $6.01MM | $2.90MM | $3.44MM |
Investing Cash Flow | $-6.01MM | $-2.90MM | $-3.44MM |
Financing Cash Flow | $48.13MM | $41.97MM | $52.76MM |
Earnings Per Share* | $0.21 | $-0.13 | $-0.06 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.